0
2022
Insomnia Market

Insomnia Market

by Therapy Type (Non pharmacological Therapy, Pharmacological Therapy): Global Opportunity Analysis and Industry Forecast, 2020-2030

✷  Report Code: A02042
Pages: 150
Apr 2022 | 17996 Views
Author(s) : Linu D, Prathmesh B , Onkar S
Tables: 86
Charts: 52
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

Insomnia Market Market Statistics - 2030

The global insomnia market was valued at $4.3 billion in 2020, and is projected to reach $6.3 billion by 2030, growing at a CAGR of 3.9% from 2021 to 2030. Insomnia is a common sleep disorder that can make it hard to fall asleep, hard to stay asleep, or cause to wake up too early and not be able to get back to sleep. The common causes of insomnia include, stress, irregular sleep schedules, poor sleeping habits, mental health disorders, such as anxiety and depression, physical illnesses and pain, medications, neurological problems, and specific sleep disorders.

The COVID-19 outbreak is anticipated to have a positive impact on the growth of the insomnia market. The COVID-19 pandemic resulted in job losses for many workers as industries were not operating properly, which contributed in rise in stress in people. Furthermore, fear of the pandemic led to depression in some people globally. Thus, increase in coronasomnia, a stress and depression associated with COVID-19 pandemic, surge the demand for insomnia drugs and drive the growth of the market.

The growth of the global insomnia market size is majorly driven by the increase in prevalence of different types of sleep disorders, such as insomnia and parasomnias, increase in mental depression, and other painful conditions. Mental depression results in difficulty in sleep. For instance, the World Health Organization (WHO) reported that around 280 million population globally suffers from depression. Thus, increase in mental depression across the global population contributes in the insomnia market growth. Furthermore, long-term consumption of some medication for chronic disease treatment possess some side effects, which are believed to affect the patient’s quality of sleep. Thus, increase in prevalence of chronic diseases, such as cancer, drives the growth of the market. For instance, according to National Institute of Cancer (NIC), an estimated 1,806,590 new cases of cancer were diagnosed in the U.S in 2020. The cancer chemotherapy results in various side effects on patents body and also affects the quality of sleep in patients.

Insomnia Market, Insomnia Treatment Market, Insomnia Market Size, Insomnia Market Share, Insomnia Market Analysis, Insomnia Market Growth, Insomnia Market Opportunity, Insomnia Market Trends, Insomnia Market Forecast

 

In addition, surge in work-related stress contributes in growth of insomnia market size. The rise in workload and hectic work schedules lead to poor quality of sleep. Furthermore, many people are working on odd time shifts, such as security officers, as well as the manufacturing industries operate for 24 hours. These odd time work shifts affect the quality and cycle of sleep. Moreover, increase in number of insomnia centers and sleep diagnostic centers, contributes in the growth of the market. The insomnia centers assist people to improve their sleep quality and sleep diagnostic centers are used as diagnostic lab for detecting sleep disorders. Furthermore, increase in adoption of non-pharmacological sleep therapy drives the growth of the market. Insomnia is commonly associated with the mental condition of person. Hence, non-pharmacological therapy, such as hypnotherapy, yoga, and cognitive behavioral therapy focus on improving a person’s mental state, and drive the insomnia industry. In addition, as many people face physical difficulties while sleeping, such as snoring, increase in need for sleeping aid devices are available to improve sleep quality. These sleeping aid devices are included in the non-pharmacological insomnia medical devices segment and it contributes in the growth of the insomnia treatment market.

Advancement in non-pharmacological therapy for sleep and new product launches in the insomnia industry are anticipated to contribute toward the growth of the market. For instance, in June 2021, Eisai Co., Ltd., a global leader that develops, manufactures, and markets a broad range of innovative life science products, announced the launch of DAYVIGO (lemborexant), which is an orexin receptor antagonist used for the treatment of insomnia in adults, characterized by difficulties with sleep onset and/or sleep maintenance. This factor is expected to drive the growth of insomnia treatment market. However, side effects associated with the long-term use of anti-insomnia drugs impede the growth of this market. In addition, the development of advanced technology in healthcare and lifestyle sectors surge the demand for the insomnia market share. Advancement in mobile phone software and health watches are available in market, which are designed to record and assist the sleeping pattern of users. These advanced software have marked an impact in diagnosis and assistance in sleep of users. Hence, handy availability of such advanced software and devices contributes in the growth of the market.

Furthermore, the COVID-19 pandemic resulted in salary pay cuts of workers, while many workers lost their jobs, which contributes in stress and depression in people. For instance, according to the World Health Organization (WHO), as of December 19, 2021, over 273 million cases were diagnosed and over 5.3 million deaths were reported globally due to COVID-19. In addition, according to a report of British Broadcasting Corporation (BBC) published in January 2021, many people and healthcare workers experienced insomnia linked to the stress of lifestyle during COVID-19, which is also known as coronosomnia. Due to the COVID-19 pandemic, increase in mental stress and depression surge the demand for insomnia treatment, and hence has a positive impact on the market.

Insomnia Market Segmentation

The insomnia market is segmented on the basis of therapy type and region. By therapy type, the market is categorized into non-pharmacological therapy and pharmacological therapy. The non-pharmacological therapy, is further fragmented into hypnotherapy, cognitive behavioral therapy, medical devices, and other non-pharmacological therapy. On the basis of pharmacological therapy, it is further segregated into prescription sleep aids and over-the-counter sleep aids.

Insomnia Market
By Therapy Type

Your browser does not support the canvas element.

Pharmacological Therapy segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Arabia, South Africa, and LAMEA).

Segment Review

Depending on therapy type, the pharmacological therapy segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to rise in prevalence of insomnia and increase in number of key player to manufacture therapeutic drug for insomnia. However, the non-pharmacological therapy segment is expected to witness considerable growth during the forecast period, due to increase in demand for yoga and cognitive behavioral therapy, and advancement in technology in the healthcare sector.

Depending on region, North America garnered the majority the insomnia market share in 2020, and is expected to dominate the insomnia market forecast period, owing to rise in prevalence of insomnia, high incidence of work related stress, and well-established healthcare infrastructure, such as presence of insomnia centers in the region. However, Asia-Pacific is expected to register the highest CAGR of 5.5% from 2021 to 2030, owing to increase in the number of geriatric population, odd time work shifts, and high population base.

The key players operating in the global insomnia market include, Minerva Neurosciences Inc., Currax Pharmaceuticals LLC, Eisai, Co. Ltd., Merck & Co. Inc., Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Ltd., Vanda Pharmaceuticals, Viatris (Mylan NV), and Zydus Cadila.

Insomnia Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the insomnia market analysis from 2020 to 2030 to identify the prevailing insomnia market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the insomnia market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global insomnia market trends, key players, market segments, application areas, and market growth strategies.

Insomnia Market Report Highlights

Aspects Details
By Therapy Type
  • Non pharmacological Therapy
  • Pharmacological Therapy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Taiwan, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Turkey, Saudi Arabia, Republic Of South Africa, Rest of LAMEA)
Key Market Players CURRAX PHARMACEUTICALS LLC, EISAI, CO. LTD, merck kgaa, darmstadt, germany, MINERVA NEUROSCIENCES INC, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Ltd, Vanda Pharmaceuticals Inc., VIATRIS INC, zydus cadila
 

Loading Table Of Content...


 
 

The global insomnia market is expected to exhibit high growth potential attributable to factors, such as rise in demand for over-the-counter (OTC) sleep aids and the emergence of therapeutics with fewer side effects.

Insomnia is a sleep disorder caused due to various factors, such as a stressful lifestyle, mental disorders, and other medical conditions. Consumption of certain drugs, caffeine, and alcohol also causes insomnia. The rise in geriatric population and growth in the incidence rate of chronic diseases further lead to increase in the use of therapeutics drug for treatment of insomnia, and propel the growth of insomnia treatment market. Furthermore, rise in stress levels among the youth, due to factors, such as job stress and intense competition increase the incidence rate of insomnia. However, the side effects caused due to excessive use of sleep medication and patent expiration of various prescription drugs are expected to restrict the market growth.

The non-pharmacological therapy segment is expected to be lucrative for new entrants and existing market players, as this form of treatment causes fewer side effects as compared to sleep medication. Furthermore, cognitive behavioral therapy is expected to be the fastest-growing segment in the near future, as it helps to identify and change the thought and behavior that causes insomnia in a patient. Moreover, in non-pharmacological therapy, the therapeutic approach can be modified as per the needs of the patient.

The application of insomnia treatment is highest in North America, due to increase in adoption of the non-pharmacological therapies, high prevalence rate of insomnia, and rise in disposable income among customers. Although, the use of therapies for the treatment of insomnia is low in Asia-Pacific and LAMEA. The adoption rate is expected to increase due to rise in disposable income, increase in incidence rate of insomnia, and growth in the number of population working at odd hours.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of insomnia market is $4,318.9 million in 2020.

A. The top companies that hold the market share in insomnia market are Minerva Neurosciences Inc., Currax Pharmaceuticals LLC, Eisai, Co. Ltd., Merck & Co. Inc., Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Ltd., Vanda Pharmaceuticals, Viatris (Mylan NV), and Zydus Cadila.

A. The market value of insomnia Market in 2021 was $4,486.1 million

A. The base year for the report is 2020.

A. Yes, insomnia companies are profiled in the report

A. The forecast period in the report is from 2021 to 2030

A. The key trends in the insomnia market are rise in incidence of chronic diseases, rise in stress level among youngsters, rise in geriatric population, and increase in healthcare expenditure

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS

Purchase Full Report of
Insomnia Market

Start reading instantly.
This Report and over 19,300+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers